Diabetes

Novartis announces European Commission approval of Beovu® for people living with diabetic macular edema

Basel, March 31, 2022 — Novartis today announced that the European Commission (EC) has approved Beovu® (brolucizumab) 6 mg for the treatment of visual impairment due to diabetic macular edema (DME). Today’s approval in DME represents the second indication for Beovu granted by the EC, which was first approved for the treatment of wet age-related…

OphthalmologyEye DisordersEye CareDiabetes
Access to Healthcare

Collaboration is strengthening care for chronic illness in Ethiopia

Working with a nonprofit, Novartis is helping train healthcare workers to diagnose and treat chronic ailments such as diabetes.

Access to HealthcareAfricaGlobal Health PartnershipsSustainable DevelopmentDiabetes
Discovery

Stepping toward regenerative medicine for diabetes

Discovery points toward treatment options beyond insulin injections

Biomedical ResearchDiseasesMedical InnovationsClinical TrialsDiabetes
Discovery

Compounds spur insulin-producing cells to replicate in the lab

Biomedical ResearchMedical InnovationsNovartis Institutes for BioMedical ResearchScientific DiscoveriesDiabetes